# NCT03466216 (NCT03466216)

> Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET

No report yet. It can be ordered.

- Drugs tested: AlphaMedix

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03466216
- Phase: PHASE1
- Status: TERMINATED
- Sponsor: Orano Med LLC
- Conditions: Neuroendocrine Tumor
- Interventions: AlphaMedix
- Enrollment: 33
- Primary outcome: To determine dose-limiting toxicity (DLT)
- Primary outcome: Incidence of treatment-emergent AEs and SAEs as assessed by CTCAE v. 4

## Indexed commentary on NCT03466216 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct03466216